title: JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab.
abstract: JC virus (JCV) DNA in the cerebrospinal fluid (CSF) provides the laboratory confirmatory diagnosis of progressive multifocal leukoencephalopathy (PML) in patients whose clinical symptoms and magnetic resonance imaging findings are consistent with PML.The Laboratory of Molecular Medicine and Neuroscience (LMMN), National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), made the confirmatory laboratory diagnosis in 35 multiple sclerosis (MS) patients treated with natalizumab. Thirteen patients had 3 or more CSF samples taken from weeks to months following PML diagnosis. Seven of the 13 patients demonstrated persistence of JCV DNA in the CSF even though all patients experienced immune reconstitution inflammatory syndrome (IRIS), 11 patients had plasma exchange, and 2 had immunoabsorption. Specific anti-JCV antibody was measured in plasma/sera samples from 25 of the 35 patients. Most of the samples showed moderate to high or rising antibody levels from the time of PML diagnosis. However, plasma from 1 patient at or near the time of PML diagnosis had a titer considered seronegative and 2 other plasma samples from patients had titers considered at baseline for seropositivity. In several PML cases, viral persistence and neurological deficits have continued for several years, indicating that once initiated, JCV infection may not entirely clear, even with IRIS.
authors.affiliation: Laboratory of Molecular Medicine and Neuroscience, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA.
authors.forename: Caroline F
authors.initials: CF
authors.lastname: Ryschkewitsch
authors.forename: Peter N
authors.initials: PN
authors.lastname: Jensen
authors.forename: Maria Chiara
authors.initials: MC
authors.lastname: Monaco
authors.forename: Eugene O
authors.initials: EO
authors.lastname: Major
mesh_terms: D000906:Antibodies / Q000097:blood; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D056915:DNA Copy Number Variations / Q000502:physiology; D004279:DNA, Viral / Q000097:blood / Q000134:cerebrospinal fluid*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D006801:Humans; D007577:JC Virus / Q000276:immunology*; D007968:Leukoencephalopathy, Progressive Multifocal / Q000188:drug therapy* / Q000209:etiology* / Q000378:metabolism / Q000821:virology; D008137:Longitudinal Studies; D008297:Male; D009103:Multiple Sclerosis / Q000134:cerebrospinal fluid / Q000150:complications* / Q000821:virology; D000069442:Natalizumab
chemical_list: D000906:Antibodies; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004279:DNA, Viral; D000069442:Natalizumab
references.citation: J Med Virol. 2003 Sep;71(1):115-23
references.pmid: 12858417
references.citation: J Virol Methods. 2004 Nov;121(2):217-21
references.pmid: 15381359
references.citation: N Engl J Med. 2006 Mar 2;354(9):924-33
references.pmid: 16510746
references.citation: Nat Neurosci. 2005 Oct;8(10):1275
references.pmid: 16189528
references.citation: J Immunol. 2001 May 1;166(9):5346-55
references.pmid: 11313370
references.citation: J Gen Virol. 2006 Oct;87(Pt 10):2951-2960
references.pmid: 16963754
references.citation: N Engl J Med. 2005 Jul 28;353(4):375-81
references.pmid: 15947078
references.citation: Lancet Neurol. 2010 Apr;9(4):438-46
references.pmid: 20298967
references.citation: J Clin Microbiol. 2000 Jan;38(1):105-9
references.pmid: 10618072
references.citation: Annu Rev Med. 2010;61:35-47
references.pmid: 19719397
references.citation: N Engl J Med. 2009 Sep 10;361(11):1081-7
references.pmid: 19741229
references.citation: J Immunol. 2002 Jan 1;168(1):499-504
references.pmid: 11751998